131 related articles for article (PubMed ID: 33264130)
1. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
2. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
Jack A; Mauro MJ; Ehst BD
J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
[No Abstract] [Full Text] [Related]
3. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib-induced atypical pityriasis rubra pilaris-like rash.
Kamat D; Chatterjee D; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(6):688-690. PubMed ID: 33159027
[No Abstract] [Full Text] [Related]
5. Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities.
Alloo A; Sheu J; Butrynski JE; DeAngelo DJ; George S; Murphy GF; LeBoeuf NR
Br J Dermatol; 2015 Aug; 173(2):574-7. PubMed ID: 25736577
[No Abstract] [Full Text] [Related]
6. Ponatinib-induced lamellar ichthyosis-like eruption.
Thakur V; Malhotra P; Lad D; Chatterjee D; Vinay K; Dogra S
Int J Dermatol; 2020 May; 59(5):e156-e157. PubMed ID: 32196645
[No Abstract] [Full Text] [Related]
7. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
8. Ichthyosiform Reaction Related to Ponatinib Therapy.
Fernández-González P; Buendía-Castaño D; Saceda-Corralo D; Jaen-Olasolo P
Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):873-875. PubMed ID: 31493826
[No Abstract] [Full Text] [Related]
9. Ponatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings.
Weber I; Gloss C; Castillo B; Smith E
Am J Dermatopathol; 2023 Jan; 45(1):64-68. PubMed ID: 36484611
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
11. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
Engel NW; Constantin A; Fowlkes S; Assouline S
J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
[No Abstract] [Full Text] [Related]
12. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.
Xu H; Busam KJ; Mauro MJ; Markova A
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469781
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
15. Ponatinib-associated panniculitis: Case report and review of the literature.
Antwi-Amoabeng D; Ghuman J; Ghuman J; Beutler BD; Ulanja MB; Kuriakose K; Bowman A
Cancer Treat Res Commun; 2021; 27():100357. PubMed ID: 33756173
[TBL] [Abstract][Full Text] [Related]
16. Drugs associated with development of pityriasis rubra pilaris: A systematic review.
Mufti A; Lytvyn Y; Maliyar K; Sachdeva M; Yeung J
J Am Acad Dermatol; 2021 Apr; 84(4):1071-1081. PubMed ID: 32687965
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
Breccia M; Abruzzese E; Iurlo A; Gozzini A; Isidori A; Gangemi D; Pregno P; Alimena G
Haematologica; 2016 Jun; 101(6):e267-8. PubMed ID: 27252515
[No Abstract] [Full Text] [Related]
18. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
19. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
20. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J
Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
